Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
GlobeNewswire
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical..
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical..
ZYNLONTA^® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted..
LONDON--(BUSINESS WIRE)--A joint partnership among Trinity Investments (“Trinity”), funds managed by Oaktree Capital Management..